Mometason Allergiespray Bei Heuschnupfen 1 A Pharma (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometason Allergiespray Bei Heuschnupfen 1 A Pharma, is a corticosteroid (glucocorticoid) presented as a nasal spray for nasal use. It treats allergic rhinitis and seasonal nasal allergy symptoms in adults and children.

GNH USA supplies Mometason Allergiespray Bei Heuschnupfen 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate nasal spray is used to manage inflammatory conditions of the nasal mucosa associated with allergic disease. - Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhea. - Seasonal allergic rhinitis: alleviates inflammation caused by pollen or other seasonal allergens. - Hay fever: improves nasal airflow and decreases mucosal swelling.

Mometasone furoate nasal spray may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Epistaxis (nosebleeds). - Headache. - Throat irritation or dryness. - Altered taste perception. - Cough.

Serious or Rare Side Effects: - Nasal septal perforation. - Severe allergic reaction (anaphylaxis). - Vision changes or cataract formation. - Adrenal suppression with systemic exposure. - Opportunistic fungal infection of the nasal cavity. - Profound or persistent nosebleeds.

Before initiating therapy, consider the following safety measures. - Assess for active nasal infection: avoid use if bacterial or fungal sinusitis is present. - Monitor intra‑ocular pressure: caution in patients with glaucoma or ocular hypertension. - Limit duration of continuous use: follow prescriber guidance to reduce risk of systemic effects. - Use with pediatric caution: adhere to age‑specific dosing recommendations. - Store at room temperature: keep in the original container, protect from moisture and heat.

Mometasone furoate nasal spray can interact with other medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid): - Concurrent potent CYP3A4 inhibitors: may increase systemic corticosteroid exposure. - Systemic corticosteroids: additive glucocorticoid effects can raise risk of adrenal suppression. - Immunosuppressants: may exacerbate infection risk.

Moderate Interactions (Monitor Closely): - Antihistamines: may increase local irritation. - Decongestant nasal sprays: could affect absorption or cause rebound congestion. - Live vaccines: nasal corticosteroid may diminish local immune response. - Antifungal agents: monitor for potential fungal overgrowth in the nasal cavity.